Thermo Fisher Scientific (NYSE:TMO) Stock Rating Upgraded by Wall Street Zen

by · The Markets Daily

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other research analysts have also weighed in on the company. CLSA initiated coverage on Thermo Fisher Scientific in a research report on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 price objective for the company. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research note on Wednesday, August 5th. Barclays lifted their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $720.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $628.78.

Read Our Latest Stock Report on Thermo Fisher Scientific

Thermo Fisher Scientific Trading Up 0.1%

Shares of NYSE TMO opened at $655.49 on Friday. Thermo Fisher Scientific has a 1 year low of $435.27 and a 1 year high of $683.63. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a 50-day moving average of $618.62 and a 200 day moving average of $535.16. The stock has a market cap of $242.37 billion, a P/E ratio of 35.26, a price-to-earnings-growth ratio of 2.74 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the prior year, the company earned $4.28 earnings per share. The business’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific will post 25.13 EPS for the current fiscal year.

Insider Activity

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This represents a 1.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 73,768 shares of company stock valued at $44,122,820. Corporate insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of hedge funds have recently added to or reduced their stakes in TMO. Polaris Financial Partners purchased a new stake in Thermo Fisher Scientific during the third quarter valued at $32,000. Kilter Group LLC purchased a new position in Thermo Fisher Scientific in the second quarter worth about $25,000. Legacy Wealth Managment LLC ID grew its stake in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the period. Allied Private Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $26,000. Finally, MBM Wealth Consultants LLC bought a new position in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $29,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

Further Reading